GLX351322, a Novel NADPH Oxidase 4 Inhibitor, Attenuates TMJ Osteoarthritis by Inhibiting the ROS/MAPK/NF-κB Signaling Pathways

Figure 7

Schematic illustration of GLX for therapy in TMJ inflammation (created with http://BioRender.com).